Igor Correia de Almeida
Corporate Officer/Principal at SeneXta Therapeutics SA
Profile
Igor Correia de Almeida is currently the Director-Executive Board at SeneXta Therapeutics SA since 2008 and an Associate Professor at The University of Texas at Austin since 2004.
He was previously an Assistant Professor at the University of Sao Paulo from 1999 to 2004 and a Lecturer at Einstein Albert Jewish Hospital Nursing School from 1989 to 1993.
He received his graduate degree from the University of Sao Paulo in 1989, his doctorate from the same institution in 1994, and his undergraduate degree from the University of Brasília in 1981.
Igor Correia de Almeida active positions
| Companies | Position | Start |
|---|---|---|
SeneXta Therapeutics SA
 SeneXta Therapeutics SA Medical SpecialtiesHealth Technology SeneXta Therapeutics SA engages in the research and development of therapies for neurodegenerative disorders. The firm provides medicines that maintain healthy brain ageing and rehabilitation after ischemic brain injury. The company was founded by Enrico Braglia and Federica Pericle in 2008 and is headquartered in Lugano, Switzerland. | Corporate Officer/Principal | 18/09/2009 |
| The University of Texas at Austin | Corporate Officer/Principal | 18/09/2009 |
Former positions of Igor Correia de Almeida
| Companies | Position | End |
|---|---|---|
| University of Sao Paulo | Corporate Officer/Principal | 01/10/2004 |
| Einstein Albert Jewish Hospital Nursing School | Corporate Officer/Principal | 01/03/1993 |
Training of Igor Correia de Almeida
| University of Sao Paulo | Graduate Degree |
| University of Brasília | Undergraduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
SeneXta Therapeutics SA
SeneXta Therapeutics SA Medical SpecialtiesHealth Technology SeneXta Therapeutics SA engages in the research and development of therapies for neurodegenerative disorders. The firm provides medicines that maintain healthy brain ageing and rehabilitation after ischemic brain injury. The company was founded by Enrico Braglia and Federica Pericle in 2008 and is headquartered in Lugano, Switzerland. | Health Technology |
| Einstein Albert Jewish Hospital Nursing School |
- Stock Market
- Insiders
- Igor Correia de Almeida
